The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Hematology"
DOI: 10.1007/s00277-024-05892-9
Abstract: Relapsed/refractory acute leukemia (R/R-AL) is associated with a low remission rate, short survival rate, and poor prognosis. Treating R/R-AL remains challenging as there is no standardized effective regimen; hence, there is a need for efficient… read more here.
Keywords: daratumumab based; leukemia; refractory acute; relapsed refractory ... See more keywords
Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01253-5
Abstract: The treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (TE-NDMM) has evolved with the introduction of daratumumab-based quadruplet regimens. Adding daratumumab to traditional triplet regimens has demonstrated improved response rates and progression-free survival… read more here.
Keywords: daratumumab based; analysis; based quadruplet; meta analysis ... See more keywords
CD38‐negative relapse in multiple myeloma after daratumumab‐based chemotherapy
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Haematology"
DOI: 10.1111/ejh.12902
Abstract: We present a case report of a patient relapsing after anti‐CD38 treatment (daratumumab). The phenotype of the disease changed during this treatment, and the myeloma clone became CD38 negative and daratumumab refractory. We expected clonal… read more here.
Keywords: cd38 negative; myeloma; treatment; cd38 ... See more keywords